Nadine McGrath
Journalist at Stockhead
Journalist specialising in finance & economy working @stockheadAU. Views expressed here are my own.
Articles
-
1 week ago |
stockhead.com.au | Nadine McGrath
Several ASX companies are building remote and critical communications globallyHarvest Technology’s Nodestream technology aims to revolutionise connectivity in demanding environmentsSpectur develops satellite communications equipment including satellite phones, devices and data terminalsAustralia is a land defined by vast distances, harsh climates and remote locations, where maintaining reliable, critical communications is especially challenging.
-
1 week ago |
stockhead.com.au | Nadine McGrath
ASX heath sector falls 4%, while broader markets down 0.79% for the same period as US tariffs Monash IVF falls after woman gives birth to a baby that was not hers after mistakenly transferred wrong embryo Imricor starts its European trial VISABL-VT trial, achieving several world-firsts and earning a Morgans’ upgrade Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and...
-
2 weeks ago |
stockhead.com.au | Nadine McGrath
Orthocell receives US FDA 510(k) approval for Remplir, its flagship nerve repair product Approval enables Orthocell to start commercial distribution into US$1.6 billion nerve repair market Orthocell forecasts significant step change in revenue, accelerating path to breakeven and profitability Perth-based regenerative medicine company Orthocell (ASX:OCC) has unlocked the door to the lucrative US market, receiving US Food and Drug Administration (FDA) clearance for its flagship nerve repair...
-
2 weeks ago |
stockhead.com.au | Nadine McGrath
ASX heath sector falls 2.1%, while broader markets also fall 3.8% for the same period as US tariffs spook global markets Regenerative medicine company Orthocell receives US FDA approval for peripheral nerve repair product Remplir HealthInvest 2025 showcased reasons for optimism despite a challenging climate with several key catalysts on horizon Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX...
-
3 weeks ago |
stockhead.com.au | Nadine McGrath
Orthocell receives US FDA 510(k) approval for Remplir, its flagship nerve repair product Approval enables Orthocell to start commercial distribution into US$1.6 billion nerve repair market Orthocell forecasts significant step change in revenue, accelerating path to breakeven and profitability Perth-based regenerative medicine company Orthocell (ASX:OCC) has unlocked the door to the lucrative US market, receiving US Food and Drug Administration (FDA) clearance for its flagship nerve repair...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 524
- Tweets
- 571
- DMs Open
- No
Clinical trials have become big business in Australia. So what are some of the #ASX health stocks undertaking trials at home?
Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022, according to @MTPConnect_AUS . Nadine McGrath looks into some of the #ASX companies undertaking trials in Australia.https://t.co/GY7rbSYznG https://t.co/z7ycwQqUnd
I've been delving into the latest report of Australia's clinical trial sector by @MTPConnect_AUS showing it has become a valuable part of the Australian economy. So just what makes Australia a 'go-to' destination for clinical trials?
Australia has established established a global reputation as a ‘go to’ destination to conduct clinical trials according to @MTPConnect_AUS with @ArgenicaT and @NeurotechInt among #ASX companies undertaking clinical trials locally. https://t.co/DvUJH2F6jW https://t.co/aeBfETqgAc
Australia has some of the best up-and-coming health and biotech companies but where to start if you're an investor. Checkout our Stockhead special investor guide. #ASX #biotech
In this special investor guide, #health and #biotech guru Tim Boreham leads Stockhead’s deep dive into the most cutting edge sector on the #ASX. https://t.co/Cb12HOZBKZ
